Blog

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Photo tsaken from Samarpana Chakraborty/X

Aug 10, 2024, 13:03

Samarpana Chakraborty: STAT3 degraders in Venetoclax resistant AML

Samarpana Chakraborty, Postdoctoral Researcher at Albert Einstein College of Medicine shared a post by Aditi Shastri, Associate Professor at Albert Einstein College of Medicine on X:

“Thrilled to share my postdoctoral work on STAT3 degraders in Venetoclax resistant AML. Grateful to Shastri lab and Aditi Shastri for giving me the opportunity to work on this fantastic project. ”

Quoting Aditi Shastri’s post:

“A new manuscript from shastri lab just dropped “A STAT3 Degrader Demonstrates Preclinical Efficacy in Venetoclax Resistant AML”. Congratulations to first author Samarpana Chakraborty and a huge thanks to amazing collabs and Kymera Therapeutics, EinsteinSCI, and Montefiore Health System.”

Source: Samarpana Chakraborty/X and Aditi Shastri/X

Aditi Shastri Albert Einstein College of Medicine cancer EinsteinSCI Kymera Therapeutics Montefiore Health System OncoDaily Oncology Samarpana Chakraborty

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage